246 related articles for article (PubMed ID: 12096086)
1. Effects of interferon beta on transcobalamin II-receptor expression and antitumor activity of nitrosylcobalamin.
Bauer JA; Morrison BH; Grane RW; Jacobs BS; Dabney S; Gamero AM; Carnevale KA; Smith DJ; Drazba J; Seetharam B; Lindner DJ
J Natl Cancer Inst; 2002 Jul; 94(13):1010-9. PubMed ID: 12096086
[TBL] [Abstract][Full Text] [Related]
2. Synergistic antitumor effects of a combination of interferons and retinoic acid on human tumor cells in vitro and in vivo.
Lindner DJ; Borden EC; Kalvakolanu DV
Clin Cancer Res; 1997 Jun; 3(6):931-7. PubMed ID: 9815768
[TBL] [Abstract][Full Text] [Related]
3. Suppression of NF-kappa B survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL.
Chawla-Sarkar M; Bauer JA; Lupica JA; Morrison BH; Tang Z; Oates RK; Almasan A; DiDonato JA; Borden EC; Lindner DJ
J Biol Chem; 2003 Oct; 278(41):39461-9. PubMed ID: 12881518
[TBL] [Abstract][Full Text] [Related]
4. Nitric Oxide Inhibits NF-κB-mediated Survival Signaling: Possible Role in Overcoming TRAIL Resistance.
Bauer JA; Lupica JA; Didonato JA; Lindner DJ
Anticancer Res; 2020 Dec; 40(12):6751-6763. PubMed ID: 33288568
[TBL] [Abstract][Full Text] [Related]
5. Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines.
Chawla-Sarkar M; Leaman DW; Borden EC
Clin Cancer Res; 2001 Jun; 7(6):1821-31. PubMed ID: 11410525
[TBL] [Abstract][Full Text] [Related]
6. Nitrosylcobalamin promotes cell death via S nitrosylation of Apo2L/TRAIL receptor DR4.
Tang Z; Bauer JA; Morrison B; Lindner DJ
Mol Cell Biol; 2006 Aug; 26(15):5588-94. PubMed ID: 16847314
[TBL] [Abstract][Full Text] [Related]
7. Effects of tamoxifen and interferon-beta or the combination on tumor-induced angiogenesis.
Lindner DJ; Borden EC
Int J Cancer; 1997 May; 71(3):456-61. PubMed ID: 9139884
[TBL] [Abstract][Full Text] [Related]
8. Nitrosylcobalamin potentiates the anti-neoplastic effects of chemotherapeutic agents via suppression of survival signaling.
Bauer JA; Lupica JA; Szugye H; Morrison BH; Haney RM; Masci RK; Lee RM; Didonato JA; Lindner DJ
PLoS One; 2007 Dec; 2(12):e1313. PubMed ID: 18074035
[TBL] [Abstract][Full Text] [Related]
9. Synergistic antitumor effects of a combination of interferon and tamoxifen on estrogen receptor-positive and receptor-negative human tumor cell lines in vivo and in vitro.
Lindner DJ; Borden EC
J Interferon Cytokine Res; 1997 Nov; 17(11):681-93. PubMed ID: 9402106
[TBL] [Abstract][Full Text] [Related]
10. Tumor apoptosis induced by epoxide-containing piperazines, a new class of anti-cancer agents.
Eilon GF; Gu J; Slater LM; Hara K; Jacobs JW
Cancer Chemother Pharmacol; 2000; 45(3):183-91. PubMed ID: 10663635
[TBL] [Abstract][Full Text] [Related]
11. Inositol hexakisphosphate kinase 2 sensitizes ovarian carcinoma cells to multiple cancer therapeutics.
Morrison BH; Bauer JA; Hu J; Grane RW; Ozdemir AM; Chawla-Sarkar M; Gong B; Almasan A; Kalvakolanu DV; Lindner DJ
Oncogene; 2002 Mar; 21(12):1882-9. PubMed ID: 11896621
[TBL] [Abstract][Full Text] [Related]
12. Reexpression of the tumor suppressor gene ARHI induces apoptosis in ovarian and breast cancer cells through a caspase-independent calpain-dependent pathway.
Bao JJ; Le XF; Wang RY; Yuan J; Wang L; Atkinson EN; LaPushin R; Andreeff M; Fang B; Yu Y; Bast RC
Cancer Res; 2002 Dec; 62(24):7264-72. PubMed ID: 12499268
[TBL] [Abstract][Full Text] [Related]
13. Potent antitumor effects of combination therapy with IFNs and monocytes in mouse models of established human ovarian and melanoma tumors.
Nakashima H; Miyake K; Clark CR; Bekisz J; Finbloom J; Husain SR; Baron S; Puri RK; Zoon KC
Cancer Immunol Immunother; 2012 Jul; 61(7):1081-92. PubMed ID: 22159517
[TBL] [Abstract][Full Text] [Related]
14. Thioredoxin reductase plays a critical role in IFN retinoid-mediated tumor-growth control in vivo.
Lindner DJ; Ma X; Hu J; Karra S; Kalvakolanu DV
Clin Cancer Res; 2002 Oct; 8(10):3210-8. PubMed ID: 12374691
[TBL] [Abstract][Full Text] [Related]
15. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
[TBL] [Abstract][Full Text] [Related]
16. p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target.
Mashima T; Oh-hara T; Sato S; Mochizuki M; Sugimoto Y; Yamazaki K; Hamada J; Tada M; Moriuchi T; Ishikawa Y; Kato Y; Tomoda H; Yamori T; Tsuruo T
J Natl Cancer Inst; 2005 May; 97(10):765-77. PubMed ID: 15900046
[TBL] [Abstract][Full Text] [Related]
17. Interferon-gamma treatment elevates caspase-8 expression and sensitizes human breast tumor cells to a death receptor-induced mitochondria-operated apoptotic program.
Ruiz-Ruiz C; Muñoz-Pinedo C; López-Rivas A
Cancer Res; 2000 Oct; 60(20):5673-80. PubMed ID: 11059759
[TBL] [Abstract][Full Text] [Related]
18. Adenovirus-mediated E2F-1 gene transfer sensitizes melanoma cells to apoptosis induced by topoisomerase II inhibitors.
Dong YB; Yang HL; Elliott MJ; McMasters KM
Cancer Res; 2002 Mar; 62(6):1776-83. PubMed ID: 11912154
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
[TBL] [Abstract][Full Text] [Related]
20. Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon beta.
Johns TG; Mackay IR; Callister KA; Hertzog PJ; Devenish RJ; Linnane AW
J Natl Cancer Inst; 1992 Aug; 84(15):1185-90. PubMed ID: 1378904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
